 |
answer text |
<p>The Department has placed no restrictions on patients accessing treatments for
advanced (stage 4) melanoma.</p><p> </p><p>The National Institute for Health and Care
Excellence (NICE) has published guidance on the following treatments for melanoma.
National Health Service commissioners are legally required to fund drugs and treatments
recommended by NICE for eligible patients within three months of final guidance.</p><p>
</p><table><tbody><tr><td><p>Appraisal number</p></td><td><p>Year of publication</p></td><td><p>Technology/condition</p></td><td><p>Recommendation</p></td></tr><tr><td><p>TA268</p></td><td><p>2012</p></td><td><p>Ipilimumab
for previously treated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended
in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA269</p></td><td><p>2012</p></td><td><p>Vemurafenib
for locally advanced or metastatic BRAF V600 mutation-positive malignant melanoma</p></td><td><p>Recommended
in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA319</p></td><td><p>2014</p></td><td><p>Ipilimumab
for previously untreated advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended
in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA321</p></td><td><p>2014</p></td><td><p>Dabrafenib
for unresectable or metastatic BRAF V600 mutation‑positive melanoma</p></td><td><p>Recommended
in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA357<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab
for advanced melanoma after disease progression with ipilimumab</p></td><td><p>Recommended
in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA366<sup>1</sup></p></td><td><p>2015</p></td><td><p>Pembrolizumab
for advanced melanoma not previously treated with ipilimumab</p></td><td><p>Recommended
in line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA384</p></td><td><p>2016</p></td><td><p>Nivolumab
for advanced (unresectable or metastatic) melanoma</p></td><td><p>Recommended in line
with marketing authorisation.</p></td></tr><tr><td><p>TA396</p></td><td><p>2016</p></td><td><p>Trametinib
in combination with dabrafenib for unresectable or metastatic melanoma</p></td><td><p>Recommended
in line with marketing authorisation.</p></td></tr><tr><td><p>TA400</p></td><td><p>2016</p></td><td><p>Nivolumab
in combination with ipilimumab for advanced melanoma</p></td><td><p>Recommended in
line with marketing authorisation and following agreement of patient access scheme.</p></td></tr><tr><td><p>TA410</p></td><td><p>2016</p></td><td><p>Talimogene
laherparepvec for unresectable metastatic melanoma</p></td><td><p>Optimised recommendation
for talimogene laherparepvec as an option for treating unresectable, regionally or
distantly metastatic (Stage IIIB, IIIC or IVM1a) melanoma that has not spread to bone,
brain, lung or other internal organs, only if: - treatment with systemically administered
immunotherapies is not suitable; and - the company provides talimogene laherparepvec
with the discount agreed in the patient access scheme.</p></td></tr><tr><td><p>TA414</p></td><td><p>2016</p></td><td><p>Cobimetinib
in combination with vemurafenib for unresectable or metastatic BRAF V600 mutation-positive
melanoma</p></td><td><p>At the time of appraisal, the technology was not considered
to be an appropriate use of NHS resources based on the data available.</p></td></tr></tbody></table><p><sup>1</sup>
pembrolizumab within its licensed indication was appraised across two separate appraisals.</p><p>
</p><p>NHS England has advised that it has carefully translated the evidence base
on which NICE has based its recommendations of clinical and cost effectiveness into
practical clarifications which directly relate to how the recommended drug indication
is incorporated into known treatment pathways in use in England.</p><p> </p><p>Each
set of clarifications is in keeping with the NICE recommendations within the marketing
authorisation of the relevant drug.</p><p> </p><p>The treatment criteria for both
Cancer Drugs Fund and baseline-funded drug indications are set out in the National
Cancer Drugs Fund List which is available at:</p><p> </p><p><a href="https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf"
target="_blank">https://www.england.nhs.uk/wp-content/uploads/2016/12/national-cdf-list-v1-15.pdf</a></p>
|
|
